• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

调节树突状细胞功能和疫苗疗效的微环境衍生因子:前列腺素受体和核受体配体的作用。

Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands.

机构信息

Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 32, 6525 GA, Nijmegen, The Netherlands.

Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA, Nijmegen, The Netherlands.

出版信息

Cancer Immunol Immunother. 2018 Nov;67(11):1789-1796. doi: 10.1007/s00262-018-2205-1. Epub 2018 Jul 11.

DOI:10.1007/s00262-018-2205-1
PMID:29998375
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6208817/
Abstract

Dendritic cells (DCs) are widely used in DC-based immunotherapies because of their capacity to steer immune responses. So far treatment success is limited and more functional knowledge on how DCs initiate and stably drive specific responses is needed. Many intrinsic and extrinsic factors contribute to how DCs skew the immune response towards immunity or tolerance. The origin and type of DC, its maturation status, but also factors they encounter in the in vitro or in vivo microenvironment they reside in during differentiation and maturation affect this balance. Treatment success of DC vaccines will, therefore, also depend on the presence of these factors during the process of vaccination. Identification and further knowledge of natural and pharmacological compounds that modulate DC differentiation and function towards a specific response may help to improve current DC-based immunotherapies. This review focuses on factors that could improve the efficacy of DC vaccines in (pre-)clinical studies to enhance DC-based immunotherapy, with a particular emphasis on compounds acting on prostanoid or nuclear receptor families.

摘要

树突状细胞 (DC) 因其能够引导免疫反应而被广泛应用于基于 DC 的免疫疗法。但到目前为止,治疗效果有限,因此需要更多关于 DC 如何启动和稳定驱动特定反应的功能知识。许多内在和外在因素影响 DC 如何使免疫反应偏向免疫或耐受。DC 的起源和类型、其成熟状态,以及它们在分化和成熟过程中在体外或体内微环境中遇到的因素,都会影响这种平衡。因此,DC 疫苗的治疗效果也将取决于接种过程中这些因素的存在。鉴定和进一步了解可调节 DC 分化和功能以产生特定反应的天然和药理学化合物,可能有助于改进现有的基于 DC 的免疫疗法。本综述重点介绍了可提高 (临床前) 研究中 DC 疫苗疗效以增强基于 DC 的免疫疗法的因素,特别强调了作用于前列腺素或核受体家族的化合物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64bf/11028369/b06bd3d7d959/262_2018_2205_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64bf/11028369/b06bd3d7d959/262_2018_2205_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64bf/11028369/b06bd3d7d959/262_2018_2205_Fig1_HTML.jpg

相似文献

1
Microenvironmental derived factors modulating dendritic cell function and vaccine efficacy: the effect of prostanoid receptor and nuclear receptor ligands.调节树突状细胞功能和疫苗疗效的微环境衍生因子:前列腺素受体和核受体配体的作用。
Cancer Immunol Immunother. 2018 Nov;67(11):1789-1796. doi: 10.1007/s00262-018-2205-1. Epub 2018 Jul 11.
2
Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy.肿瘤微环境相关的树突状细胞缺陷:增强肿瘤免疫治疗的一个靶点。
Pharmacol Res. 2020 Sep;159:104980. doi: 10.1016/j.phrs.2020.104980. Epub 2020 Jun 3.
3
Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.赋能树突状细胞癌症疫苗接种:联合策略的作用。
Cytotherapy. 2018 Nov;20(11):1309-1323. doi: 10.1016/j.jcyt.2018.09.007. Epub 2018 Oct 22.
4
Harnessing dendritic cells in cancer.利用树突状细胞治疗癌症。
Semin Immunol. 2011 Feb;23(1):42-9. doi: 10.1016/j.smim.2011.01.003. Epub 2011 Feb 3.
5
Guiding the "misguided" - functional conditioning of dendritic cells for the DC-based immunotherapy against tumours.引导“迷途”——树突状细胞功能调节在基于树突状细胞的肿瘤免疫治疗中的作用。
Eur J Immunol. 2011 Jan;41(1):18-25. doi: 10.1002/eji.201040543. Epub 2010 Dec 9.
6
Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.采用封闭式电穿孔系统对自体肿瘤裂解物负载树突状细胞疫苗进行免疫治疗实体瘤。
Anticancer Res. 2013 Jul;33(7):2971-6.
7
Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.精准癌症免疫疗法:优化基于树突状细胞的策略以诱导针对个体患者肿瘤的肿瘤抗原特异性T细胞应答。
J Immunother. 2015 May;38(4):155-64. doi: 10.1097/CJI.0000000000000075.
8
The role of dendritic cells in cancer.树突状细胞在癌症中的作用。
Int Rev Cell Mol Biol. 2019;348:123-178. doi: 10.1016/bs.ircmb.2019.07.006. Epub 2019 Aug 1.
9
Dendritic Cells and Cancer Immunity.树突状细胞与癌症免疫
Trends Immunol. 2016 Dec;37(12):855-865. doi: 10.1016/j.it.2016.09.006. Epub 2016 Oct 25.
10
Optimizing dendritic cell-based immunotherapy for cancer.优化基于树突状细胞的癌症免疫疗法。
Expert Rev Vaccines. 2007 Jun;6(3):333-45. doi: 10.1586/14760584.6.3.333.

引用本文的文献

1
Feasibility Study for the Use of Gene Electrotransfer and Cell Electrofusion as a Single-Step Technique for the Generation of Activated Cancer Cell Vaccines.基因电转移和细胞电融合作为一种生成激活癌细胞疫苗的单步技术的可行性研究。
J Membr Biol. 2024 Dec;257(5-6):377-389. doi: 10.1007/s00232-024-00320-5. Epub 2024 Aug 12.
2
Dendritic Cells in Cancer Immunology and Immunotherapy.癌症免疫学与免疫治疗中的树突状细胞
Cancers (Basel). 2024 Feb 28;16(5):981. doi: 10.3390/cancers16050981.
3
Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors.

本文引用的文献

1
Liver X Receptor Nuclear Receptors Are Transcriptional Regulators of Dendritic Cell Chemotaxis.肝 X 受体核受体是树突状细胞趋化性的转录调节因子。
Mol Cell Biol. 2018 Apr 30;38(10). doi: 10.1128/MCB.00534-17. Print 2018 May 15.
2
Lipid Droplets as Immune Modulators in Myeloid Cells.脂滴作为髓系细胞中的免疫调节剂。
Trends Immunol. 2018 May;39(5):380-392. doi: 10.1016/j.it.2018.01.012. Epub 2018 Feb 22.
3
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.用于癌症治疗的树突状细胞疫苗再度兴起。
肥大细胞和树突状细胞作为实体瘤免疫治疗中的细胞免疫检查点。
Int J Mol Sci. 2022 Sep 21;23(19):11080. doi: 10.3390/ijms231911080.
4
Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy.肿瘤微环境中树突状细胞的代谢:用于免疫治疗。
Front Immunol. 2021 Feb 24;12:613492. doi: 10.3389/fimmu.2021.613492. eCollection 2021.
5
Regulation of the germinal center response by nuclear receptors and implications for autoimmune diseases.核受体对生发中心反应的调节及其对自身免疫性疾病的影响。
FEBS J. 2020 Jul;287(14):2866-2890. doi: 10.1111/febs.15312. Epub 2020 Apr 19.
6
Trial watch: dendritic cell vaccination for cancer immunotherapy.试验观察:用于癌症免疫治疗的树突状细胞疫苗接种
Oncoimmunology. 2019 Jul 18;8(11):e1638212. doi: 10.1080/2162402X.2019.1638212. eCollection 2019.
Trends Cancer. 2018 Feb;4(2):119-137. doi: 10.1016/j.trecan.2017.12.007.
4
Dendritic cells as cancer therapeutics.树突状细胞作为癌症治疗方法。
Semin Cell Dev Biol. 2019 Feb;86:77-88. doi: 10.1016/j.semcdb.2018.02.015. Epub 2018 Mar 21.
5
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.自然杀伤细胞刺激 cDC1 细胞向肿瘤微环境募集,促进癌症免疫控制。
Cell. 2018 Feb 22;172(5):1022-1037.e14. doi: 10.1016/j.cell.2018.01.004. Epub 2018 Feb 8.
6
Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.提高基于树突状细胞的黑色素瘤免疫疗法疗效的策略
Front Immunol. 2017 Nov 20;8:1594. doi: 10.3389/fimmu.2017.01594. eCollection 2017.
7
Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.利用一种诱导免疫原性细胞死亡的新策略来改进用于淋巴瘤免疫治疗的基于树突状细胞的疫苗。
Oncoimmunology. 2017 Jul 31;6(11):e1356964. doi: 10.1080/2162402X.2017.1356964. eCollection 2017.
8
The Orphan Nuclear Receptor NR4A3 Is Involved in the Function of Dendritic Cells.孤儿核受体NR4A3参与树突状细胞的功能。
J Immunol. 2017 Oct 15;199(8):2958-2967. doi: 10.4049/jimmunol.1601911. Epub 2017 Sep 11.
9
Trial watch: Dendritic cell-based anticancer immunotherapy.试验观察:基于树突状细胞的抗癌免疫疗法。
Oncoimmunology. 2017 May 12;6(7):e1328341. doi: 10.1080/2162402X.2017.1328341. eCollection 2017.
10
PPARγ in dendritic cells and T cells drives pathogenic type-2 effector responses in lung inflammation.树突状细胞和T细胞中的过氧化物酶体增殖物激活受体γ(PPARγ)在肺部炎症中驱动致病性2型效应反应。
J Exp Med. 2017 Oct 2;214(10):3015-3035. doi: 10.1084/jem.20162069. Epub 2017 Aug 10.